Patent ID: 8232277

Claim:
A butane bridge modified tetra-O-substituted nordihydroguaiaretic acid derivative compound (BB-Sb4N), having the following general structure (Formula VI), and its pharmaceutically acceptable salts: wherein each Z is selected from the group consisting of H, —CHO, —CN, —CH 2 CH 3 , —CH 2 Cl, —CH 2 Br and —CH 2 F; wherein Y is selected from the group consisting of: -A-R; —(CH 2 ) x Hal, where x is an integer of 1 to 10, and Hal is a halogen atom, namely any of chlorine, fluorine, bromine or iodine; —(CH 2 CH 2 O) y H, where y is an integer of 1 to 10; and a carbamate-bonded group selected from the group consisting of: where n is an integer of 1 to 6, T 1 is a saturated linear hydrocarbon chain of 2-6 carbons and optionally 1-3 halogen atoms, T 2 is a 5- to 7-member ring optionally containing 0-3 double bonds and optionally containing 1-3 atoms of any of O, N and S, and T 3 is methyl or ethyl; wherein when Y is -A-R, the side chain A is selected from the group consisting of a C 2 -C 6 linear saturated hydrocarbon chain, optionally with 1-5 heteroatoms selected from the group consisting of O, N and S, bonded to the respective hydroxy residue O groups of NGDA through an ether bond; and 1-5 units of a polyethylene glycol (PEG) chain; the end group R is selected from the group consisting of: a 5- to 7-member carbocyclic ring selected from the group consisting of a fully saturated ring with 1 to 3 N, O or S heteroatoms; a ring containing 1 to 3 double bonds for a 6- or 7-member ring and 1 to 2 double bonds for a 5-member ring, with 1 to 3 N, O or S heteroatoms for the 5 to 7 member ring; a ring containing a carbamate bond, a urea bond, a carbonate bond or an amide bond; and a water soluble group selected from the group consisting of an alkali metal salt of sulfonic acid; an alkali metal salt of phosphonic acid; a sugar and a polyhydroxy group or a pharmaceutically acceptable salt thereof.